Fus (Fused In Sarcoma) is an important component in the neurobiology of neurodegenerative [diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases. This page provides detailed information about its structure, function, and role in disease processes.
FUS (Fused in Sarcoma), also known as TLS (Translocated in Liposarcoma), is a multifunctional RNA-binding protein encoded by the FUS gene on chromosome 16p11.2. [It belongs to the FET family of [proteins[/[proteins[/[proteins[/[proteins[/[proteins[/[proteins[/[proteins[/proteins (FUS, EWSR1, TAF15) and plays essential roles in [DNA] repair, transcription regulation, RNA splicing, and RNA transport. FUS was first identified as part of a chromosomal translocation in human myxoid liposarcoma (Crozat et al., 1993), but gained prominence in neurodegeneration research when mutations in FUS were identified as causative for familial [amyotrophic lateral sclerosis (ALS)[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX-- and [Frontotemporal Dementia (FTD)[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd--TEMP--/diseases)--FIX-- (Kwiatkowski et al., 2009; Vance et al., 2009).
FUS is a 526-amino acid protein that is predominantly nuclear in healthy [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- but mislocalizes to the cytoplasm in disease states, where it forms pathological aggregates through aberrant liquid-liquid phase separation (LLPS). Mutations in FUS account for approximately 4–5% of familial ALS cases and are particularly associated with aggressive juvenile-onset forms of the disease (Mackenzie et al., 2010). FUS pathology is also found in a subset of FTD cases lacking tau] or [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- inclusions, classified as FTLD-FUS (Neumann et al., 2009).
FUS is a 526-amino acid protein with a modular domain architecture that is asymmetrically divided into a low complexity domain (LCD) and an RNA-binding domain (RBD) (Kato et al., 2012):
QGSY-rich prion-like domain (PrLD, residues 1–165): An intrinsically disordered N-terminal region enriched in glutamine, glycine, serine, and tyrosine residues. This domain mediates liquid-liquid phase separation and is critical for FUS self-assembly into biomolecular condensates. Post-translational modifications including phosphorylation regulate its phase behavior (Monahan et al., 2017).
RGG1 domain (residues 165–267): The first arginine-glycine-glycine repeat region, which contributes to RNA binding and phase separation through electrostatic interactions.
RNA Recognition Motif (RRM, residues 285–370): A canonical RNA-binding domain that recognizes specific RNA motifs including GGUG and GUGGU sequences (Lerga et al., 2001).
RGG2 domain (residues 370–422): The second RGG repeat region.
Zinc finger domain (ZnF, residues 422–453): A C2/C2-type zinc finger that binds both RNA and DNA and contributes to nucleic acid binding specificity.
RGG3 domain (residues 453–501): The third RGG repeat region.
Nuclear Localization Signal (NLS, residues 510–526): A PY-NLS at the C-terminus recognized by the nuclear import receptor Transportin-1 (TNPO1/Karyopherin-β2). Most ALS-causing mutations cluster in or near this domain, disrupting nuclear import (Dormann et al., 2010).
FUS is one of the most abundant RNA-binding proteins in the nucleus and participates in virtually every step of RNA metabolism (Lagier-Tourenne et al., 2012):
FUS rapidly localizes to sites of DNA damage, where it facilitates the [DNA damage response[/mechanisms/[dna-damage-response[/mechanisms/[dna-damage-response[/mechanisms/[dna-damage-response--TEMP--/mechanisms)--FIX-- (DDR) (Mastrocola et al., 2013). Through its interaction with poly(ADP-ribose) (PAR), FUS is recruited to DNA double-strand breaks within seconds, preceding other repair factors. FUS facilitates both homologous recombination and non-homologous end joining repair pathways. Impaired DNA damage repair has been demonstrated in cortical [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- from ALS patients carrying FUS mutations, linking FUS dysfunction to genomic instability and [neurodegeneration[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/mechanisms.
Under cellular stress, FUS is recruited to stress granules (SGs)—cytoplasmic ribonucleoprotein assemblies that temporarily halt translation of non-essential mRNAs. FUS contributes to SG assembly through its prion-like domain (Li et al., 2013). Pathological mutations promote persistent SG formation and impair SG disassembly, potentially serving as nucleation sites for irreversible FUS aggregation.
FUS has become a paradigmatic protein for studying biomolecular condensate formation through liquid-liquid phase separation (LLPS) (Patel et al., 2015):
Normal LLPS: FUS undergoes reversible phase separation to form dynamic liquid-like droplets in the nucleus, where it participates in transcription hubs, DNA repair foci, and paraspeckles. The prion-like LCD drives droplet formation, while the RBD modulates condensate properties through RNA engagement.
Aberrant Phase Transitions: Under pathological conditions—including disease-associated mutations, elevated protein concentration, or prolonged stress—FUS droplets undergo maturation from liquid to gel to solid states, forming amyloid-like fibrils (Murakami et al., 2015). This irreversible "aging" of condensates is a key step in pathological aggregation.
Regulation: FUS phase behavior is modulated by post-translational modifications (phosphorylation of serine residues in the LCD by DNA-PK reduces LLPS), RNA binding (RNA opposes aggregation at physiological concentrations), and chaperone activity (DNAJB6 can maintain FUS in a loose gel-like state, preventing fibrilization).
Mutations in FUS cause approximately 4–5% of familial ALS and ~1% of sporadic ALS cases. Over 50 disease-associated mutations have been identified, with the majority clustering in the C-terminal NLS domain (Shang & Bhang, 2012):
FUS-ALS shows two distinct pathological patterns correlating with disease severity: (1) early-onset aggressive disease with basophilic inclusions and round FUS-immunoreactive neuronal cytoplasmic inclusions (P525L, R522G), and (2) later-onset disease with tangle-like inclusions and frequent glial cytoplasmic inclusions (R521C) (Mackenzie et al., 2011).
FUS pathology defines a subset of [FTD[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd--TEMP--/diseases)--FIX-- known as FTLD-FUS, which accounts for approximately 9% of all FTLD cases with ubiquitin-positive inclusions (Neumann et al., 2009). Three subtypes are recognized:
Notably, unlike FUS-ALS, FTLD-FUS cases rarely harbor FUS mutations, suggesting a different pathogenic mechanism involving wild-type FUS aggregation.
ASOs targeting FUS mRNA to reduce FUS protein levels have shown promise in preclinical models. Intrathecal delivery of FUS-targeting ASOs reversed motor neuron degeneration in mouse models (Korobeynikov et al., 2022). Jacifusen (ION363), an ASO targeting FUS, was the first personalized ASO therapy administered to an ALS patient under compassionate use (Nature Medicine, 2022).
Molecular chaperones that prevent aberrant FUS phase transitions represent a promising therapeutic avenue. DNAJB6 promotes non-toxic FUS condensate gelation and inhibits neurotoxicity (Nature Communications, 2025). [Heat shock proteins[/entities/[heat-shock-proteins[/entities/[heat-shock-proteins[/entities/[heat-shock-proteins--TEMP--/entities)--FIX-- and the [ubiquitin-proteasome system[/entities/[ubiquitin-proteasome-system[/entities/[ubiquitin-proteasome-system[/entities/[ubiquitin-proteasome-system--TEMP--/entities)--FIX-- are also being explored as strategies to clear FUS aggregates.
Compounds that stabilize FUS in its liquid-like state and prevent aberrant solid-state transitions are under investigation. Targeting the Transportin-1–FUS interaction to restore nuclear import is another active area of drug discovery.
FUS shares structural and functional similarities with [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX--, another RNA-binding protein implicated in [ALS[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX-- and [FTD[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd--TEMP--/diseases)--FIX--. Both proteins contain prion-like domains and undergo pathological phase transitions. However, FUS and [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- pathology are generally mutually exclusive in patient tissues, suggesting parallel but distinct disease pathways (Ling et al., 2013).
FUS also interacts with [SOD1[/proteins/[sod1-protein[/proteins/[sod1-protein[/proteins/[sod1-protein--TEMP--/proteins)--FIX--, another ALS-associated protein. Co-aggregation of FUS with other RNA-binding proteins, including hnRNPA1, hnRNPA2/B1, and EWSR1, has been observed in disease models, indicating that FUS toxicity may extend beyond the protein itself to a broader disruption of RNA metabolism (Kim et al., 2013).
The study of Fus (Fused In Sarcoma) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.